中山醫學大學機構典藏 CSMUIR:Item 310902500/12469
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17938/22957 (78%)
造访人次 : 7402086      在线人数 : 137
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/12469


    题名: Antibody against Distinct Cytoplasmic Antigens in Patients Receiving Anti-Hepatitis C Therapy with Interferon and Ribavirin in Taiwan
    作者: Sun, Yu-Shu;Lee, Ming-Shih;Lin, Chun-Che;Lee, Ming-Yung;Hsieh, Ming-Chang;Lin, Ching-Pin;Tsay, Gregory J
    贡献者: 中山醫學大學
    关键词: Anti-RR antibody;HCV;Peg-IFN/ribavirin
    日期: 2014-12-01
    上传时间: 2015-12-09T01:51:42Z (UTC)
    出版者: 研發處育成中心暨產學合作組
    摘要: The aim of the present study was to examine the presence of autoantibodies in patients with hepatitis C virus (HCV) infection receiving combination pegylated interferon (Peg-IFN) and ribavirin therapy. Sera were obtained from 46 patients with HCV infection receiving combination Peg-IFN and ribavirin (Peg-IFN/ribavirin) treatment and 152 patients with HCV infection receiving Peg-IFN therapy only at Chung Shan Medical University Hospital, Taiwan. The serum samples were evaluated for the presence of anticytoplasmic antibody by indirect immunofluorescence assay (IIF) of HEp-2 cells. HEp-2 cells were also cultured with Peg-IFN (100 U/ml), ribavirin (100 μg/ml) and Peg-IFN/ribavirin. Anti-histone antibody (AHA) was determined by ELISA. The rod and ring index (RRI) was calculated by counting the numbers of rods and rings in 100 cells. Patients with HCV infection treated with Peg-IFN/ribavirin had a higher prevalence of anti-cytoplasmic rod and ring (anti-RR) antibodies than those not treated with Peg-IFN/ribavirin. RRI increased with duration of therapy and decreased after discontinuing therapy. When HEp-2 cells were cultured with Peg-IFN/ribavirin or ribavirin, RRI increased with culture time. Further, AHA increased with increasing anti-RR antibody in patients receiving Peg-IFN/ribavirin therapy. In conclusion, anti-RR antibody is found in HCV patients receiving Peg-IFN/ribavirin therapy and the frequency of anti-RR antibody is correlated with therapy time, suggesting that combination Peg- IFN/ribavirin and ribavirin alone play a role in the production of anti-RR antibodies. Anti-RR antibody should be considered a serological marker for patients receiving Peg-IFN/ribavirin therapy.
    URI: https://ir.csmu.edu.tw:8080/ir/handle/310902500/12469
    關聯: 中山醫學雜誌 25卷2期, P73 - 78
    显示于类别:[研發處] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    v24n2p73-78.pdf期刊論文560KbAdobe PDF425检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈